Study M1018
Study name | Ritter C 2022 |
Title | Evaluation of prefrontal gamma-aminobutyric acid and glutamate levels in individuals with major depressive disorder using proton magnetic resonance spectroscopy |
Overall design | The aim of this study was to investigate changes in gamma-aminobutyric acid, glutamate and glutamine, glutamate, and glutamine levels in a voxel in the left dorsolateral prefrontal cortex of participants with no, past, and current major depressive disorder (MDD) using proton magnetic resonance spectroscopy (1H-MRS). The sample consisted of 251 healthy controls (control group), 98 participants with a history of past MDD (past MDD group), and 47 participants who met the diagnostic criteria for current MDD (MDD group). Neurotransmitter concentrations in the left dorsolateral prefrontal cortex were measured using 3-T 1H-MRS. Metabolite quantification was reported in absolute concentrations. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD |
Sample size | 298 |
Tissue | Central; Brain; Dorsolateral prefrontal cortex; |
Platform | MRS; MRS: 3-T GE Discovery MR750 wholebody MRI scanner (GE Healthcare); |
PMID | |
DOI | |
Citation | Ritter C, Buchmann A, Muller ST, et al. Evaluation of prefrontal gamma-aminobutyric acid and glutamate levels in individuals with major depressive disorder using proton magnetic resonance spectroscopy. JAMA Psychiatry. 2022 Dec 1;79(12):1209-1216. |
Metabolite |
